Tracon Pharmaceuticals (NASDAQ:TCON), TCP Capital Corp (NASDAQ:TCPC) - Earnings Scheduled For February 25, 2021 benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
- Full-year 2020 Total Revenues Increased 9% to $1.86 billion
- Company Dose-escalates in PHEarless, a Phase 1/2 Study with BMN 307 Gene Therapy for the Treatment of Phenylketonuria (PKU); the Third Potential Therapeutic Modality in its PKU Franchise
- During the Fourth Quarter, BioMarin Announced Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
- Marketing Applications for Vosoritide to Treat Children with Achondroplasia under Review in Europe and the U.S.; Committee for Medicinal Products for Human Use (CHMP) Opinion Expected in June 2021
- In January 2021, BioMarin Announced Positive Phase 3 Results with Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set; Mean Annualized Bleed Rate was 0.9 in Subset Dosed More than Two Years Ago
Biomarin Pharmaceutical (NASDAQ:BMRN) unveils its next round of earnings this Thursday, February 25. Get prepared with Benzinga's ultimate preview for .
/PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual conferences. An audio.
Share this article
Share this article
SAN RAFAEL, Calif., Feb. 18, 2021 /PRNewswire/ BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Goldman Sachs partner and executive in the life sciences industry, Maykin Ho, Ph.D., to its Board of Directors. We are thrilled to welcome Maykin to BioMarin s Board of Directors. She brings a breadth and depth of experience in the healthcare industry and finance to an already exceptional board, said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin. Maykin brings an important perspective to support BioMarin s growth trajectory as we strive to address the unmet medical needs of people affected by rare genetic diseases and deliver scientific breakthroughs.